# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Yul Brynner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML020-SYN
- Date: 2026-09-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Simon Achterberg, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Tissue sequencing result and start of first-line pembrolizumab. **S**

## History of present illness

Mr. Brynner returns one week later. The tissue sequencing report arrived yesterday: KRAS G12V and TP53 mutations, with no EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, NTRK, HER2, or NRG1 alteration, in agreement with the plasma result. With the thoracic oncologist he chose pembrolizumab alone, given every 3 weeks, rather than with chemotherapy, because it is a preferred first-line option at his PD-L1 level and spares him the fatigue and nausea of chemotherapy while he works toward the stage. His first infusion is this afternoon. The dental examination four days ago found no problems. He is unchanged: weak voice, a little morning cough, no pain, and steady weight. The visit ran long with treatment teaching, and the symptom questionnaire was not completed. **S**

| Element | Detail |
|---|---|
| Tissue sequencing | KRAS G12V and TP53; no actionable alteration |
| Treatment decision | Pembrolizumab 200 mg every 3 weeks, first dose today |
| Dental status | Examination four days ago; no work needed |
| Symptoms | Unchanged; no pain |
| Tobacco | No tobacco |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Morning dry cough; no hemoptysis |
| Gastrointestinal | Negative | Bowels regular; no abdominal pain |
| Endocrine | Negative | No heat or cold intolerance, thirst, or dizziness |
| Integumentary | Negative | No rash or itching |

4 systems reviewed. **S**

## Current medications

- Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 96% on room air; weight 71.8 kg; BMI 22.7 kg/m². All vital signs are synthetic.

TSH: 2.1 mIU/L; Free T4: 1.2 ng/dL; Morning cortisol: 14.2 ug/dL; ALT: 26 U/L; AST: 23 U/L; Alkaline phosphatase: 101 U/L; Total bilirubin: 0.6 mg/dL; Creatinine: 0.9 mg/dL; eGFR: 92 mL/min/1.73 m²; Glucose: 94 mg/dL; Calcium: 9.5 mg/dL; Hemoglobin: 13.6 g/dL; White cell count: 7.6 10*3/uL; Platelets: 284 10*3/uL. All results are synthetic.

## Change since baseline

- ALT: 24 U/L at baseline, 26 U/L at this visit **S**
- AST: 22 U/L at baseline, 23 U/L at this visit **S**
- Alkaline phosphatase: 98 U/L at baseline, 101 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.6 mg/dL at this visit **S**
- Creatinine: 0.9 mg/dL at baseline, 0.9 mg/dL at this visit **S**
- eGFR: 92 mL/min/1.73 m² at baseline, 92 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 94 mg/dL at this visit **S**
- Calcium: 9.6 mg/dL at baseline, 9.5 mg/dL at this visit **S**
- Hemoglobin: 13.8 g/dL at baseline, 13.6 g/dL at this visit **S**
- White cell count: 7.9 10*3/uL at baseline, 7.6 10*3/uL at this visit **S**
- Platelets: 290 10*3/uL at baseline, 284 10*3/uL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 71.8 kg |
| Voice | Breathy, low-volume voice |
| Lungs | Slightly reduced breath sounds at the left apex |
| Skin | No rash |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Adenocarcinoma of the lung, stage IVB, PD-L1 70 percent, no actionable alteration** (C34.12). Biomarker testing complete. With PD-L1 of 50 percent or more and no actionable alteration, pembrolizumab monotherapy is a preferred first-line regimen. Baseline TSH 2.1, free T4 1.2, morning cortisol 14.2, liver tests, glucose, creatinine, calcium, and blood count normal. **S**
   - Pembrolizumab 200 mg intravenously today, then every 3 weeks.
   - Written list of immune-related warning symptoms and the 24-hour oncology telephone line given.
   - Laboratory panel before each infusion; response CT about nine weeks after starting.
   - Zoledronic acid with the second cycle, so that a first-dose reaction is not confused with an early immune-related event.
2. **Bone metastases** (C79.51). No pain; dental examination done. **S**
   - First zoledronic acid dose with cycle 2.
3. **Left vocal fold paralysis** (J38.01). Unchanged. **S**
   - Injection medialization in two weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Broad molecular profiling (tissue and plasma) | At diagnosis of advanced nonsquamous NSCLC: EGFR, ALK, ROS1, BRAF, KRAS (including G12C), MET exon 14, RET, NTRK, HER2, NRG1, and PD-L1; repeat at progression | Completed today | Tissue sequencing: KRAS G12V and TP53; no actionable alteration; concordant with plasma |
| Laboratory | Immune-related adverse event laboratory panel | Before each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicated | Completed today | Baseline: TSH 2.1, free T4 1.2, morning cortisol 14.2, ALT 26, AST 23, alkaline phosphatase 101, bilirubin 0.6, glucose 94, all normal |
| Laboratory | Blood count, kidney function, and calcium before systemic therapy | Before each cycle | Completed today | Hemoglobin 13.6, white cells 7.6, platelets 284, creatinine 0.9 (eGFR 92), calcium 9.5 |
| Imaging | Response assessment imaging | Every 6 to 12 weeks on active systemic therapy | Due | First response CT about nine weeks after starting |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Morning dry cough; unchanged |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco |
| Survey | Distress and symptom screening (NCCN Distress Thermometer, ESAS) | Every visit; at minimum at key transitions | Deferred | Not done today, at the start of treatment, a key transition: the visit ran long with treatment teaching. Deviation from the every-visit and key-transition screen. No harm resulted: the palliative care team assessed his symptoms and distress in full a week later, and the next scores were lower. Corrective action: the ESAS and distress thermometer are now completed on a tablet at check-in, before the clinician sees him |
| Survey | Cancer-related fatigue screening | Every visit | Completed today | Tired by evening, unchanged; no daytime naps |
| Examination | Weight and dietary review | Each follow-up | Completed today | 71.8 kg, stable |
| Medication safety | Dental evaluation before a bone-modifying agent | Baseline, then periodically on zoledronic acid or denosumab | Completed today | Examination four days ago: no active disease, no extractions needed |
| Referral | Early integrated palliative care | Within eight weeks of diagnosis of advanced cancer | Referred | First visit next week |
| Self-management | Voice and work support | As needed | Referred | Injection medialization in two weeks; voice therapy started |
| Medication safety | Chemotherapy-induced peripheral neuropathy | Every visit during and after platinum or taxane | Not indicated | Pembrolizumab alone; no platinum or taxane |

## Goal progress

- Tissue diagnosis, full staging, PD-L1, and comprehensive biomarker results before any systemic therapy, within three weeks of presentation. Outcome by 2026-09-22: Diagnosis and stage by two weeks; PD-L1 at two weeks and tissue sequencing at three weeks; pembrolizumab started the day the sequencing was reviewed. **S**
- First palliative care visit within eight weeks of diagnosis. In progress; target 2026-10-13. **S**
- A voice strong enough for rehearsal by the second cycle. In progress; target 2026-10-13. **S**
- No grade 2 or higher immune-related adverse event missed: laboratory panel before each infusion and symptom review at each visit. In progress; target 2026-10-13. **S**
- Zoledronic acid started only after a dental examination and normal calcium and kidney function. In progress; target 2026-10-13. **S**

## Medication changes

- Started: Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021), American Society of Clinical Oncology (Schneider BJ et al., J Clin Oncol 2021;39(36):4073-4126)
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017), American Society of Clinical Oncology (Ferrell BR et al., J Clin Oncol 2017;35(1):96-112)
- NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026), National Comprehensive Cancer Network

## Follow-up

- First pembrolizumab infusion this afternoon. Palliative care next week. Voice injection in two weeks. Cycle 2 in three weeks with the laboratory panel and the first zoledronic acid dose. Call the oncology line for any warning symptom. **S**
- Next scheduled visit 2026-10-13: cycle 2 review: immune-related adverse event monitoring, symptoms, and return to work. **S**
